232 related articles for article (PubMed ID: 31043945)
1. Expanding the Indication for Novel Theranostic 177Lu-Dotatate Peptide Receptor Radionuclide Therapy: Proof-of-Concept of PRRT in Merkel Cell Cancer.
Kasi PM; Sharma A; Jain MK
Case Rep Oncol; 2019; 12(1):98-103. PubMed ID: 31043945
[TBL] [Abstract][Full Text] [Related]
2. Peptide Receptor Radionuclide Therapy.
Hofland J; Brabander T; Verburg FA; Feelders RA; de Herder WW
J Clin Endocrinol Metab; 2022 Nov; 107(12):3199-3208. PubMed ID: 36198028
[TBL] [Abstract][Full Text] [Related]
3. A Care Process Model to Deliver
Kasi PM; Maige CL; Shahjehan F; Rodgers JM; Aloszka DL; Ritter A; Andrus ML; Mcmillan JM; Mody K; Sharma A; Jain MK
Front Oncol; 2018; 8():663. PubMed ID: 30687638
[No Abstract] [Full Text] [Related]
4. Prevalence of hitherto unknown brain meningioma detected on
Parghane RV; Talole S; Basu S
World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748
[TBL] [Abstract][Full Text] [Related]
5. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors.
Kjaer A; Knigge U
Scand J Gastroenterol; 2015 Jun; 50(6):740-7. PubMed ID: 25959100
[TBL] [Abstract][Full Text] [Related]
6. Guidance on
Abbott A; Sakellis CG; Andersen E; Kuzuhara Y; Gilbert L; Boyle K; Kulke MH; Chan JA; Jacene HA; Van den Abbeele AD
J Nucl Med Technol; 2018 Sep; 46(3):237-244. PubMed ID: 30076245
[No Abstract] [Full Text] [Related]
7. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.
Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES
Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377
[TBL] [Abstract][Full Text] [Related]
8. Practical Considerations for Implementation of
Soulek DK; Mastascusa NJ; Martin ME; Graves SA
J Nucl Med Technol; 2022 Jun; ():. PubMed ID: 35701215
[TBL] [Abstract][Full Text] [Related]
9. Metastatic Neuroendocrine Tumor with Extensive Bone Marrow Involvement at Diagnosis: Evaluation of Response and Hematological Toxicity Profile of PRRT with (177)Lu-DOTATATE.
Basu S; Ranade R; Thapa P
World J Nucl Med; 2016; 15(1):38-43. PubMed ID: 26912977
[TBL] [Abstract][Full Text] [Related]
10. Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors.
Zandee WT; Brabander T; Blažević A; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; de Herder WW
J Clin Endocrinol Metab; 2019 Apr; 104(4):1336-1344. PubMed ID: 30566620
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review.
Maqsood MH; Tameez Ud Din A; Khan AH
Cureus; 2019 Jan; 11(1):e3986. PubMed ID: 30972265
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin Receptor Avidity in Gastrointestinal Stromal Tumors: Theranostic Implications of Gallium-68 Scan and Eligibility for Peptide Receptor Radionuclide Therapy.
Loaiza-Bonilla A; Bonilla-Reyes PA
Cureus; 2017 Sep; 9(9):e1710. PubMed ID: 29188154
[TBL] [Abstract][Full Text] [Related]
13. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
14. Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life.
Severi S; Grassi I; Nicolini S; Sansovini M; Bongiovanni A; Paganelli G
Onco Targets Ther; 2017; 10():551-557. PubMed ID: 28203088
[TBL] [Abstract][Full Text] [Related]
15. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
[TBL] [Abstract][Full Text] [Related]
16. Favorable Response of Metastatic Merkel Cell Carcinoma to Targeted 177Lu-DOTATATE Therapy: Will PRRT Evolve to Become an Important Approach in Receptor-Positive Cases?
Basu S; Ranade R
J Nucl Med Technol; 2016 Jun; 44(2):85-7. PubMed ID: 26471333
[TBL] [Abstract][Full Text] [Related]
17. 177Lu-DOTATATE PRRT in Recurrent Skull-Base Phosphaturic Mesenchymal Tumor Causing Osteomalacia: A Potential Application of PRRT Beyond Neuroendocrine Tumors.
Basu S; Fargose P
J Nucl Med Technol; 2016 Dec; 44(4):248-250. PubMed ID: 27634982
[TBL] [Abstract][Full Text] [Related]
18. Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids.
Naraev BG; Ramirez RA; Kendi AT; Halfdanarson TR
Clin Lung Cancer; 2019 May; 20(3):e376-e392. PubMed ID: 30910575
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine Tumor Therapy:
Mittra ES
AJR Am J Roentgenol; 2018 Aug; 211(2):278-285. PubMed ID: 29949416
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms.
Waseem N; Aparici CM; Kunz PL
J Nucl Med; 2019 Jul; 60(7):882-891. PubMed ID: 30850504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]